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History-Adjusted Marginal Structural Models
to Estimate Time-Varying Effect Modification
Maya L. Petersen, Steven G. Deeks, Jeffrey N. Martin, and Mark J. van der Laan
Abstract
Much of epidemiology and clinical medicine is focused on the estimation of
treatments or interventions administered over time. In such settings of longitu-
dinal treatment, time-dependent confounding is often an important source of bias.
Marginal structural models are a powerful tool for estimating the causal effect of
a treatment using observational data, particularly when time-dependent confound-
ing is present. Recent statistical work presented a generalization of marginal struc-
tural models, called history-adjusted marginal structural models. Unlike standard
marginal structural models, history-adjusted marginal structural models can be
used to estimate modification of treatment effects by time-varying covariates. Es-
timation of time-dependent causal effect modification is frequently of great prac-
tical relevance. For example, clinical researchers are often interested in how the
prognostic significance of a biomarker for treatment response can change over
time. This article provides a practical introduction to the implementation and
interpretation of history-adjusted marginal structural models. The method is illus-
trated using a clinical question drawn from the treatment of HIV infection. Obser-
vational cohort data from San Francisco, California, collected between 2000 and
2004, are used to estimate the effect of time until switching antiretroviral therapy
regimen among patients receiving a non-suppressive regimen, and how this effect
differs depending on CD4 T cell count.
INTRODUCTION 
Dynamic treatment regimens are decision rules for altering treatment in response 
to changes in patient or pathogen characteristics. Such dynamic decision-making is 
central to the practice of medicine; clinicians select a future treatment plan that is 
expected to optimize a patient's long-term outcome, then modify this treatment plan over 
time in response to changes in disease progression. For example, patient risk factors and 
sequential measurements of blood pressure inform when antihypertensive medication is 
initiated. Similarly, the dose of antidepressant medication is often modified in response to 
changes in patient symptoms and side effects. And, as will be described here, the decision 
to switch antiretroviral therapy regimen for an Human Immunodeficiency Virus (HIV)-
infected patient is based on the virologic and immunologic response to treatment, as well 
as side effects and other factors. 
Despite the crucial and ubiquitous role of dynamic decision making in medicine, 
rigorous identification of candidate dynamic treatment regimens and evaluation of their 
effectiveness remains relatively rare.  Randomized controlled trials can be used to 
compare candidate dynamic treatment regimens; however these trials do not themselves 
identify the decision rules to be compared. We suggest that observational data provide a 
rich source for identifying dynamic treatment regimens expected to optimize patient 
outcome. We introduce a new methodology, history-adjusted marginal structural models 
(HA-MSM) (1), which directly identifies a specific type of optimal dynamic treatment 
regimen using observational data.  
HA-MSM generalize marginal structural models (MSM), introduced by Robins, 
(2-4). MSM are a powerful statistical tool for causal inference. Epidemiological and 
clinical research often relies on longitudinal treatment status and covariate data. When 
treatment status changes over time, conventional analytic approaches (such as standard 
multivariable regression methods) often fail to provide valid causal inference about the 
effect of treatment.  Marginal structural models address this well-recognized problem of 
time-dependent confounding.  
While MSM address confounding by time-dependent covariates, to date they have 
been restricted to the estimation of effect modification by baseline covariates only. Thus 
it has been possible to use this methodology to address questions such as "What is the 
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effect of a treatment and how does it differ between study members with different 
covariate values at entry to the study?", but not "How does the effect of a treatment differ 
as a result of changing values of a covariate over the course of the study?". As a result, 
MSM have not been applied to identify optimal dynamic treatment regimens. 
As will be outlined here, HA-MSM use the identical causal framework as 
standard MSM, but unlike MSM, can be used to identify a rule for making treatment 
decisions over time, based on time-varying covariates, that represents a specific type of 
optimal dynamic treatment regimen. This dynamic treatment regimen corresponds closely 
to the needs of clinical practitioners, in that it allows a practitioner to use a patient's most 
recent measured covariates to update, at each patient visit, the future treatment plan that 
will maximize the patient's expected long-term outcome.  
This paper provides a practical introduction to HA-MSM; the formal statistical 
theory and assumptions are presented in (1). We illustrate our methodology with an 
example drawn from the treatment of HIV using antiretroviral therapy (ART). 
 
ANTIRETOVIRAL THERAPY FOR THE TREQTMENT OF HIV INFECTION: 
WHEN TO SWITCH? 
HIV evolves rapidly in the presence of a selective pressure.  This leads to the 
accumulation of mutations that confer "resistance" to antiretroviral drugs.  The optimal 
manner to avoid the rapid emergence of resistance-associated mutations is therefore to 
completely suppress viral replication. This can be achieved in many patients with  
standard three-drug combination regimens (5).  However, a substantial proportion of 
treated patients fail to achieve complete viral suppression.   Such patients are often 
switched to a new regimen, but this can lead to the use of all available therapeutic 
options.   Since many patients with incomplete viral suppression continue to do well 
immunologically (and therefore clinically) (6-8), many clinicians choose not to switch to 
a new regimen as long as CD4 T cell counts remain elevated.   Hence, clinicians are often 
faced with a dilemma in patients with detectable viremia on therapy:  should they switch 
therapy as soon as possible, thereby risking using up all drugs quickly and exposing 
patients to increasingly complicated and potentially toxic regimens?  Or should they 
maintain patients on a partially suppressive regimen as long as they are doing well 
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immunologically and clinically, even though this approach will allow the ongoing 
accumulation of drug-resistance mutations that can limit future therapeutic options? (For 
a review of this issue, see Deeks (9).) 
In this paper, we estimate the effect of non-suppressive therapy on future CD4 T 
cell count, and estimate how this outcome differs depending on a patient's current CD4 T 
cell count, and time spent on non-suppressive therapy. Based on these estimates, we 
identify a rule for deciding when to switch to a new antiretroviral therapy that will 
maximize the patient's expected CD4 T cell count in the future. Data for these analyses 
are drawn from the Study on the Consequences of the Protease Inhibitor Era (SCOPE), an 
observational cohort of HIV-infected patients in San Francisco. Participants are seen at 4-
month intervals.  At each visit, they complete interviewer- and self-administered 
questionnaires examining domains including socioeconomic status (housing, income, 
employment), antiretroviral medication use and adherence, occurrence of opportunistic 
infection or malignancy, and recreational drug use. Plasma HIV RNA levels and 
CD4/CD8 T cell counts are measured at each visit, as well as between visits according to 
physician discretion.   Importantly, decisions as to when and how to modify therapy are 
made by primary care providers based on standard of care. 
For our current analysis, we retrospectively identified subjects from SCOPE who 
experienced virologic failure while being observed in this study.    Subjects became 
eligible for our analyses (t=0) if they failed to achieve an undetectable HIV RNA levels 
(< 75 copies RNA/mL) by week 24 on a new regimen, or if they rebounded from an 
undetectable level.  The exposure of interest was time until switching to a new therapy. 
This can be summarized as a binary variable at each time point, indicating whether or not 
a subject has switched off of his or her original non-suppressive ART regimen.  We only 
allowed subjects to switch once in our analyses. The method can be easily extended, 
however, to encompass more complex treatment patterns. 
In the sections which follow, we rely on this data structure to illustrate our 
methodology. In the final section, we present the results of our analyses. 
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THE COUNTERFACTUAL FRAMEWORK 
The causal effect of a treatment on an individual can be defined as the difference 
in the individual's outcome with and without the treatment. Such outcomes are termed 
counterfactual because only one is observed for each individual. MSM are models of how 
the population distribution of these counterfactual outcomes changes as a result of 
changes in treatment. 
We begin by introducing some standard notation. Treatment over the course of 
the study (t=0,...,K) is denoted ))(),...,0(()( KAAKA = , and covariates  are denoted 
)1( +KL , where treatment occurs after covariates at a given time point, and K+1 is the 
end of follow-up. In our HIV example, )(KA  is a vector of binary variables, consisting 
of one for each time point until a subject switches therapy, and zero thereafter. For each 
possible time until switching, )1( +KLa  denotes the counterfactual CD4 T cell counts 
and other covariates over time that would have been observed if the subject had switched 
therapy at the time implied by aA = .  The outcome for a given time point t is the 
counterfactual CD4 T cell count measured 8 months in the future under the switching 
time indicated by a , denoted )8( +taY . 
If we observed the counterfactual CD4 T cell counts for each individual under 
each possible switch time, we could estimate the causal effect of waiting to switch 
therapy by simply comparing the counterfactual outcomes under different switch times. 
However, we only observe the CD4 T cell counts for each individual under a single (non-
random) switch time. As a result, in order to estimate the effect of time until switching 
therapy on CD4 T cell count using the observed data, we must assume that the covariates 
we measured are sufficient to control for confounding. For example, within strata defined 
by our measured confounders, there must be no unmeasured variables that predict, at any 
time point, both probability of switching treatment and also CD4 T cell count 8 months in 
the future. 
Under this assumption, we could use standard MSM to ask:  "At baseline (when 
virologic failure occurs), how does time until switching to a new regimen affect CD4 T 
cell count 8 months later? How does this effect differ depending on a patient's CD4 T cell 
count at baseline?" However, an MSM assumed at a single time point does not allow us 
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to estimate how the effect of future non-suppressive therapy may change as a result of 
changes in a patient's CD4 T cell count, or how this information should be used to decide 
when to switch a patient to a new ART regimen. HA-MSM directly address these 
questions. 
 
HISTORY-ADJUSTED MARGINAL STRUCTURAL MODELS 
HA-MSM rely on the identical causal framework as standard MSM, but estimate 
a different parameter of interest. HA-MSM assume a standard MSM at each time point 
during the study, which models counterfactual outcomes indexed by treatment that occurs 
after that time point, conditional on some subset of the observed history up till that time 
point. In addition, HA-MSM allow us to assume a common model across time points. In 
other words, HA-MSM model some parameter of the counterfactual outcome if the study 
population were to follow their observed treatment history up till time j, followed by a 
specified counterfactual future treatment history until outcome is measured, conditional 
on  a subset of (possibly time-varying) covariates and/or treatment history measured 
before time j. In this article, we will focus on HA-MSM concerned with the mean of 
these counterfactual outcomes; however, the same framework can be readily adopted to 
model any other parameter.  
We denote a future longitudinal treatment regimen, beginning at time j and 
continuing until the outcome is measured m time points later, as 
))1(),...1(),(()1,( −++≡−+ mjajajamjja , for mKj −+= 1,...,0 . The effect 
modifiers of interest are denoted ))1−j(),(()( ⊂ AjLjV , a subset of a subject's treatment 
and covariate history up till time j. For each time point in the study for which the 
outcome m time points later is defined, HA-MSM model the expectation of the 
counterfactual outcome )(
)1,(),1(
mjY mjjajA +−+− , conditional on V(j), under each possible 
future treatment regimen. Thus, HA-MSM are concerned with estimation of the 
following parameter: ))j(| VE )((
)1,(),1(
mjY mjjajA +−+− , where j=0,…,K+1-m. 
Applied to our example, future antiretroviral treatment from time j until the 
outcome is measured, denoted )1,( −+ mjja , consists of a vector of counterfactual 
treatment decisions a(j),…a(j+m-1) , where a(t)=0 if a subject has switched treatment at 
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or before time t, and otherwise a(t)=1. This vector of future treatment decisions exists for 
each subject beginning at each time point j=0,…,K+1-m.  We summarize )1,( −+ mjja  
as c , which represents the future time (beginning at time point j) that the 
subject will spend on his/her original failing therapy before either switching or the 
outcome is measured.  The current CD4 T cell count at time j is denoted CD4(j)=S(j), a 
subset of the full covariate history measured over time, 
∑ −+=≡ 1 )()( mj jl laj
)( jL . For each time point j, we 
are interested in the mean counterfactual CD4 T cell count m=8 months later among 
individuals who have not yet switched therapy, if they were to switch therapy at a 
specified counterfactual time after j.  
To address this question, we might assume the following model: 
))()(4)()(4)((
)1)1(())(4),1(|)8((
543210
)(),1(
jjcjCDjcjjCDjc
jAIjCDjAjYE jcjA
×+×++++
×=−=−+−
ββββββ  (1)  
81,...,0 −+= Kj . 
In other words, we might assume that, among individuals who have not yet 
switched treatment (A(j-1)=1), counterfactual CD4 T cell count 8 months later depends  
on additional time until switching (c(j)), but the magnitude of this effect differs 
depending on the duration a patient has already spent on non-suppressive therapy (j) and 
current CD4 T cell count (CD4(j)).  
This model allows us to estimate the effect of each additional month until 
switching to a new therapy on CD4 T cell count 8 months later, among patients who have 
been on their current non-suppressive therapy for different durations and have different 
current CD4 T cell counts. For example, by testing whether 04 =β  we are testing the 
hypothesis that a subject's current CD4 T cell count modifies the effect of future time 
until switching. 
 
INVERSE PROBABILTIY OF TREATMENT WEIGHTED ESTIMATION 
Several HA-MSM estimators are available; here, we focus on the inverse 
probability of treatment weighted (IPTW) estimator, which can be implemented using 
standard software. The IPTW estimator can be understood as simply a weighted least 
squares estimator. For each time point j in the study, each subject receives a weight 
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which is informally the inverse of the subject's probability of receiving the treatment that 
he or she actually received, from time point j until the outcome is measured. If a subject 
has a longitudinal treatment regimen beginning at time point j that occurs frequently in 
the data among subjects with his covariate and treatment history, he receives a small j-
specific weight. In contrast, if the subject has an unusual longitudinal treatment regimen 
given his covariates, the subject will receive a large weight. In our HIV example, patients 
whose CD4 T cell counts have recently declined are more likely to switch therapy. A 
subject that did not switch therapy despite a recent decline in CD4 T cell count would 
thus have a small predicted probability of receiving her observed treatment, and receive a 
large weight.  
The first step in implementing the IPTW estimator is to model the treatment 
mechanism, or  fit a predictive model of treatment at each time point t,  given the 
observed past up till that time point: ))(),1(|)(( tLtAtAg − ,  t K,...,0= .  For example, 
we model the treatment decision (switch therapy or not) made at every time point t using 
logistic regression. A simple model of the treatment mechanism might be: 
KttCDtCDtAtA ,...,0  ),(4))(4,11(|)(logit( 10 =+==− θθ ,  (2)  
where CD4(t) is CD4 T cell count at time t. Recall that once a subject switches, he/she is 
no longer at risk of switching in the future. Thus, when fitting our model of the 
probability of staying on therapy at a given time point (A(t)=1), we fit the model only 
among subjects who have not  already switched before that time point (A(t-1)=1). 
For the IPTW estimator to be consistent, the estimate of the treatment mechanism 
must be consistent and enough covariates must be included in the treatment model so that 
outcome is independent of treatment assignment conditional on the variables in the model 
(or in other words, there must not be additional confounders that do not appear in the 
model of the treatment mechanism). 
For each time point j=0,...,K+1-m, the model of the treatment mechanism 
(equation 2) is used to estimate the denominator of the j-specific weight:  
∏−+
=
−
1
))(),1(|)((
mj
jl
lLlAlAg  
For subjects who do not switch therapy before the outcome is measured m months later, 
the denominator of the j-specific weight is 
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  ∏−+
=
=−=
1
))(4,1)1(|1)((
mj
jl
lCDlAlAP
For subjects who have not switched therapy by time j, but who switch at some point 
T=j+C(j)  before the outcome is measured (C(j)< m), the denominator of the j-specific 
weight is  
  ∏−
=
=−==−=−
1
))(4,1)1(|1)(()))(4,1)1(|1)((1(
T
jl
lCDlAlAPTCDTATAP
Recall that subjects who have already switched therapy by time j do not contribute to our 
counterfactuals of interest.  
The weight is then calculated as the inverse of the denominator. Note that the 
same subject will have a separate weight for each time point j in the study, with 
denominators corresponding to the probability that the subject received his/her observed 
treatment from that time point j until the outcome is measured. Once each subject has 
been assigned a set of K+1-m weights, a weighted least squares regression is run using 
standard software, with each subject contributing K+1-m weighted lines of data.  
 
THE HA-MSM DYNAMIC TREATMENT REGIMEN 
For each time point during the study, HA-MSM identify the future static 
treatment regimen that will maximize the expectation of the outcome, given treatment 
history and covariates of interest up till that time point. Recall that a static treatment 
regimen allows treatment to change over time, but not in response to changing patient 
covariates.  In our example, model 1 allows us to estimate how much longer subjects 
should remain on their current non-suppressive therapy in order to maximize their 
expected CD4 T cell count 8 months later, given how long they have already been on 
non-suppressive therapy and their current CD4 T cell count. Among individuals who 
have not already switched, the effect of each additional month waiting to switch therapy 
is jjCD 541 )(4 βββ ++ . 
At any given time point, this expression provides an optimal static future 
treatment regimen. When this expression is negative, each additional month waiting to 
switch will lead to depletion of CD4 T cells, suggesting that an individual should be 
switched immediately. When the expression is positive, waiting to switch will result in a 
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gain in CD4 T-cells, suggesting that the patient should be maintained on his current 
regimen.  
The optimal future static treatment regimen estimated by HA-MSM in turn 
suggests an interesting dynamic treatment regimen. Recall that a dynamic treatment 
regimen is a rule or function that gives a recommended treatment decision at each time 
point, based on patient characteristics measured up till the time point. The dynamic 
treatment regimen identified by HA-MSM consists of following, at each time point, the 
first action of an individual's optimal static future treatment regimen at that time point. At 
subsequent time points, the optimal static future treatment regimen can then be updated in 
response to changes in covariates and treatment history.  
 
RESULTS: WHEN TO SWITCH ANTIRETROVIRAL THERAPY 
In our example, we identified from SCOPE a total of 100 patients who 
experienced loss of viral suppression on antiretroviral therapy and who had a  CD4 T cell 
count measured 8 months later. Since a patient could contribute more than one episode of 
loss of suppression, we evaluated a total of 116 unique treatment episodes. Most patients 
had been on multiple treatment regimens prior to inclusion in our analysis.   
The median time to switch after onset of failure was 6 months. Tables 1 and 2 describe 
the sample at time of confirmed virologic failure. 
Cross-validated data-adaptive logistic regression (using the Deletion/ 
Substitution/ Addition algorithm (10)) was used to model the probability of switching 
therapy at each time point (the treatment mechanism) based on 40 candidate covariates 
(this included all covariates in tables 1 and 2, the time elapsed since loss of suppression, 
and plasma HIV RNA levels, defined as below of above the assay limit). The resulting fit 
of the treatment mechanism is shown in table 3. 
The following standard MSM were used to estimate: 
1.  The marginal effect of time until switching therapy (c) on CD4 T cell count 8 
months after loss of suppression (Y(8)): cYE c 10))8(( ββ +=  
2. The effect of time until switching therapy on CD4 T cell count 8 months after loss 
of suppression (baseline), conditional on CD4 T cell count at baseline (CD4(0)): 
)0(4)0(4))0(4|)8(( 3210 CDcCDcCDYE c ×+++= ββββ  
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Table 4 shows the estimates of causal effects based on these models, as well as 
the corresponding non-causal associations (unadjusted for confounding). The MSM 
results suggest that, while waiting to switch therapy is generally associated with a loss of 
CD4 T cells (9.9 cells/month), waiting to switch is not detrimental among patients with 
high CD4 T cell counts (> 218 cells) at the time of virologic failure. The discrepancy 
between the causal coefficients, as estimated using MSM, and the non-causal associations 
(-9.9 vs. 4.9, -13.1 vs. -9.5) suggests the presence of significant time-dependent 
confounding. 
At each time point, HA-MSM were used to estimate the effect of additional time 
until switching therapy among patients who remained on their original therapy, 
conditional on current CD4 T cell count. Nineteen individuals achieved re-suppression of 
the virus during follow-up despite remaining on the same therapy (an indicator that 
virologic failure was not due to resistance). As we aimed to estimate the effect of waiting 
to switch therapy among individuals with loss of viral suppression due to the presence of 
resistant virus, HA-MSM were fit only among those individuals with no history of re-
suppression (I(Supp=0)). Our HA-MSM aimed to replicate the results of a randomized 
trial in which individuals currently on a non-suppressive therapy regimen and with no 
history of re-suppression on this regimen were assigned to switch to a new therapy at a 
random time in the future. 
Two sets of HA-MSM analyses were conducted. In the first, the following model 
was assumed, and separate coefficients were estimated for each time point j. 
))(4)()(4)(()0(1)1((
))(4,1)1(|)8((
3210
)()1(
jCDjcjCDjcSuppIjAI
jCDjAjYE jcjA
×+++×=×=−=
=−+−
ββββ  
Based on the resulting coefficient estimates for the first nine months (j=0,..,8), figure 1 
plots the estimated effect of each additional month waiting to switch therapy for three 
current CD4 T cell counts.  
Figure 1 suggests that the effect of additional time until switching differs 
depending on the amount of time an individual has already spent on non-suppressive 
therapy, as well as on the individual's current CD4 T cell count. Specifically, in the 
months immediately subsequent to loss of virologic suppression, waiting to switch 
therapy appears beneficial among individuals with high current CD4 T cell counts, but 
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detrimental in those with low CD4 T cell counts. In contrast, among the population that 
have already spent at least five months on their current non-suppressive therapy, 
additional time waiting to switch has a negligible effect on future CD4 T cell count, 
regardless of an individual's current CD4 T cell count. This effect modification may be 
due in part to the fact that the population remaining on non-suppressive therapy for at 
least five months is a different population than the original group failing therapy; they are 
likely to have remained on non-suppressive therapy precisely because they were better 
able to tolerate it. 
In the second set of analyses, a single model was fit for the first nine time points 
(j=0,..,8), now assuming common parameters across time and including time spent on 
non-suppressive therapy as a covariate in the model: 
))(4)()()(4)()(4)((
)0()1)1(())(4,1)1((|)8((
654210
)(),1(
jjCDjcjjcjCDjcjCDjc
SuppIjAIjCDjAjYE jcjA
××+×+×+++
×=×=−==−+−
ββββββ  
Using this common model, the estimated effect of each additional month until switching 
therapy is  
jjCDjjCD
jjCDjjCD
××−×+×+−=
×+++
)(401.09.1)(405.04.10
)(4)(4 6541 ββββ  
Table 5 shows the estimates of causal effect of switching based on this model 
(plotted for three CD4 T cell values in figure 2). This fit provides us with a decision rule 
for when to switch therapy; when this expression is negative, switch therapy 
immediately. When this expression is positive, wait until the next month, then re-evaluate 
the expression based on current CD4 T cell count and elapsed time.  
 
DISCUSSION 
The HA-MSM presented in this paper represent an important generalization of 
MSM methodology. MSM are well-established as powerful tools for causal inference, 
particularly in the setting of longitudinal data. In this article we have introduced an 
extension of MSM to identify and estimate time-dependent causal effect modification.  
We have further illustrated how HA-MSM make possible the identification of a specific 
type of dynamic treatment regimen. The dynamic treatment regimens identified by HA-
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MSM will be most appropriate as candidates for future clinical trials when they include 
all major effect modifiers of the exposure of interest (1). 
Alternative statistical methods currently available for identifying and evaluating 
dynamic treatment regimens, such as Structural Nested Mean Models (SNMM) and G-
computation (11-13), require substantial programming effort to implement, perhaps 
explaining the paucity of epidemiologic research aimed at estimating dynamic treatment 
regimens. In contrast, as illustrated in this paper, HA-MSM can be implemented using 
standard software. In addition, SNMM and G-computation both identify dynamic 
treatment regimens aimed at optimizing an outcome at a fixed time-point. In contrast, in 
the example presented, HA-MSM were used to identify a dynamic treatment regimen 
aimed at optimizing a continuously changing outcome (CD4 T cell count 8 months in the 
future). In many applications, optimizing such a "moving" outcome, rather than an 
outcome at a fixed time point, may indeed be the researchers’ goal.  
In conclusion, HA-MSM identify treatment decision rules based on time-
dependent covariates that are expected to optimize patient outcome. Identification of such 
dynamic treatment regimens is a crucial application in the medical sciences, in addition to 
other fields that rely on dynamic decision-making. We anticipate that these models will 
prove a useful tool in multiple fields of applied research. 
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TABLE 1.  Characteristics of sample at time of failure (continuous variables).1 
 
Characteristic 1st Quartile Median Mean 3rd Quartile Missing 
Plasma HIV RNA level  365.5 4317 34190 24940 0
CD4 T cell count 175.5 261.5 321 428.8 0
CD8 T cell count 726.8 1022 1168 1497 0
Percent Average Adherence (self report) 100 100 92.36 100 0
Year Diagnosed with HIV 1986 1989 1989 1993 2
Age 44.2 50.5 49.9 55.5 0
Year of first antiretroviral treatment 1991 1996 1995 1997 0
Peak HIV RNA level (lab records) 46020 177500 242300 381200 0
Nadir CD4 T cell count (lab records) 36.25 72.5 118.3 165 0
Number of PI2 drugs experienced 2 3 3.241 4 0
Number of NRTI3 drugs experienced 4 5 4.819 6 0
Number of NNRTI4 drugs experienced 0 1 0.9138 1 0
 
   
 
                                                 
1Among 100 individuals (116 episodes) with a know time of viral failure, and follow-up for at least 8 
months following time of failure.  
2 Protease inhibitor 
3 Nucleoside reverse transcriptase inhibitor 
4 Non-nucleoside reverse transcriptase inhibitor 
Hosted by The Berkeley Electronic Press
 
TABLE 2.  Characteristics of sample at time of failure (Categorical Variables).5 
 
Characteristc N (%) Missing
Treatment history  0
Enfuvurtide 8 (7%)  
Tenofovir 41 (35%)  
Lamivudine 115 (99%)  
Mono/dual ART6 57 (49%)  
Current Treatment  0
Protease inhibitor 87 (75%)  
Nucleoside reverse transcriptase inhibitor 113 (97%)  
Non-nucleoside reverse transcriptase inhibitor 22 (19%)  
Lab Frequency  0
Most Recent HIV RNA level > than one month prior 49 (42%)  
Most Recent CD4  T cell count > than one month prior 42 (36%  
Subject Characteristics   
History of intravenous drug use 43 (37%) 0
Male 100 (86%) 0
Sexual orientation "Man who has sex with men" 79 (69%) 1
Homeless within past year 6 (5%) 0
Current diagnosis with an opportunistic disease 25 (22%) 0
Self-identified HIV risk group  0
Man having sex with men 79 (68%)  
Intravenous drug use ever 22 (19%)  
Heterosexual Intercourse 8 (7%)  
Other 7 (6%)  
Race/ethnicity  0
White 51 (44%)  
African-American/Black 35 (30%)  
Latino/Hispanic/ Mexican-American 17 (15%)  
Other 13 (11%)  
Crack use (past 4 months)   1
Every day 3 (3%)  
Once a week 6 (5%)  
Once a month 3 (3%)  
Less than once a month 7 (6%)  
Never 96 (83%)  
Methamphetamine use (past 4 months)  1
Once a week 2 (2%)  
Once a month 4 (3%)  
Less than once a month 3 (3%)  
Never 106 (92%)  
                                                 
5 Among 100 individuals (116 episodes) with a know time of viral failure, and follow-up for at least 8 
months following time of failure 
6 ART=Antiretroviral treatment 
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Alcohol Use (past 4 months)  1
At least once a day 10 (9%)  
Nearly every Day 6 (5%)  
3-4 times a week 7 (6%)  
1-2 times a week 26 (23%)  
2 or 3 times total 14 (12%)  
Once 12 (10%)  
Never 40 (35%)  
Education (highest year of school completed)  0
Grades 7-11 16 (14%)  
High School/GED 24 (21%)  
Some College 46 (40%)  
4 Years College/BS/BA 19 (16%)  
Some/Completed Graduate School 11 (9%)  
Income (yearly household)  0
<=$6000 5 (4%)  
$6001-$12,000 50 (43%)  
$12,001-$18,000 20 (17%)  
$18,001-$24,000 14 (12%)  
$24,001-$30,000 2 (2%)  
$30,001-$36,000 4 (3%)  
$36,001-$75,000 13 (11%)  
>$75,000 8 (7%)  
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TABLE 3. Odds ratios for switching treatment based on data-adaptive fit of 
treatment mechanism.7 8 
 
Covariate Odds Ratio 
Current diagnosis with an opportunistic disease 1.22 
Number of protease inhibitor drugs experienced 1.11 
Most recent HIV RNA level undetectable  0.44 
Percent average adherence (per 10%) 0.92 
Most recent CD4 T cell count (per 100 CD4 T cells) 0.92 
Nadir CD4 T cell count (per 100 CD4 T cells) 1.05 
Most recent HIV RNA level more than one month prior 0.90 
Age (per 5 years) 0.90 
 
                                                 
7 Note: Variables for treatment mechanism selected among larger sample of non-suppressed in SCOPE 
cohort: 255 people, 368 episodes, including people with unknown loss of suppression time and missing 
outcome. The coefficients on the selected model (corresponding to the Odds Ratios reported here) were 
then refit on the population with known loss of suppression time. 
8 Note: Standard errors and P-values not shown, to emphasize that role of the treatment mechanism in 
construction of weights, rather than for the purposes of causal interpretation. 
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TABLE 4. Non-causal associations and estimated causal effects of time until switching 
therapy on CD4 T Cell Count 8 months after loss of suppression.9 10 
 
  Coefficient 95% CI11 12
Associations for Each Additional Month Until Switching Therapy 
Unadjusted Association: 
E(Y(8)|C=c)  
 4.9 -6.3, 16.8
Multivariable Regression: 
E(Y(8)|CD4(t=0),C=c)   
-9.5 
0.05 * CD4(t=0)
-17.7, -1.3
0.03,  0.08
Causal Effects of Each Additional Month Until Switching Therapy 
Standard MSM:   
E(Yc (8))  
- 9.9 -21.1, 2.9 
Conditional Standard MSM: 
E(Yc (8)|CD4(t=0))  
-13.1 c
0.06 * CD4(t=0)
-22.5, -4.8
0.03, 0.09
 
 
 
 
                                                 
9 “C” and “c” denote, respectively, the observed and counterfactual number of months after baseline (viral 
failure)  of exposure to original non-suppressive therapy 
10  CD4 (t=0)  denotes observed CD4 T cell count at baseline (time of viral failure). 
11 Based on 100 Bootstrap samples 
12 CI=Confidence interval 
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TABLE 5. Coefficients from HA-MSM model for first 9 time points (j=0,..,8).13 
Estimated effect of each additional month until switching therapy, given current CD4 T 
cell count (CD4(j)) and  elapsed time since failure occurred (j). 
 
Coefficient  95% CI14 15
-10.4  
 0.05 x CD4(j)  
 1.9  x j  
- 0.01 x  CD4(j) x j 
-18.5, -4.0
0.03, 0.08
-0.03, 3.4
-0.02, -0.003
  
 
 
                                                 
13 Estimated among people who have not yet switched therapy and have not re-suppressed the virus. 
14 Based on 100 Bootstrap samples 
15 CI = Confidence Interval 
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FIGURE 1. Separate HA-MSM fit at each of first 9 time points.16 
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16 Estimated among people who have not yet switched therapy and have not re-suppressed the virus. 
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FIGURE 2: Single HA-MSM fit for first 9 time points.17 
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17 Estimated among people who have not yet switched therapy and have not re-suppressed the virus. 
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